New research suggests that methods recently developed for the molecular classification of breast cancer may be unsuitable for selecting patients for clinical trials. Dr Jorge Reis-Filho , from the Breakthrough Breast Cancer Research Centre at The Institute of Cancer Research (ICR), says molecular tests to classify breast cancer subtypes need much more development to ensure they are accurate and consistent enough to be used in a clinical setting… (Source: Health News from Medical News Today)

Further information:

Article source

Related posts:

1. A fuzzy gene expression-based computational approach improves breast cancer prognostication
2. Chemicals Suspected In Breast Cancer, US Experts Want Tests
3. Report of the Integrative Molecular Cancer Epidemiology International Symposium, Lyon, France
4. Intra-operative measurement of tumour size in breast cancer and its comparison with other methods: A prospective study
5. PTEN breast cancer susceptibility: a matter of dose